Mesoblast’s Ryoncil Sees Positive Covid-19 Experiment Results
To keep our readers updated on the developments of Covid-19 we have been paying close attention to any experimental drugs that have made news recently in regards to their effectiveness against the virus. Today we’ll be taking a look at Remestemcel-L, a cellular therapy product from the Australian company Mesoblast.
It was recently reported that in a study of Covid-19 patients that had moderate to severe symptoms related to the virus (acute respiratory distress syndrome) there was an 83 % survival rate with two infusions of the experimental drug, known as Ryoncil. At the beginning of the month, the FDA had accepted Mesoblast’s license application for Ryoncil as a treatment for GVHD, or Acute graft-versus-host disease. The drug is designed as an intravenous infusion and contains stem cells derived from the bone marrow of an unrelated donor. A far different experimental drug than we discussed before, as those were influenza or antiviral medications.
In this study, nine out of 12 patients came off of ventilators within 10 days, and seven of those patients have been discharged from the hospital. It is important to note that all of the patients had received other experimental therapies before receiving the treatment. Considering the 9% of patients well enough to come off of ventilators treated with standard care, The CEO of Mesoblast had this to say about the experiment…
“The remarkable clinical outcomes in these critically ill patients continue to underscore the potential benefits of Remestemcel-L as an anti-inflammatory agent in cytokine release syndromes associated with high mortality, including acute graft versus host disease and COVID-19 ARDS,”
“We intend to rapidly complete the randomized placebo-controlled Phase II/III trial in COVID-19 ARDS patients to rigorously confirm that Remestemcel-L improves survival in these critically ill patients.”
It is good to see these rates coming out of these experiments, but it is important to note that this was an extremely small sample size and cannot be seen as a confirmed treatment. As more testing is done and we learn more about the experimental drugs being used to treat Covid-19, be sure to check back here at our blog to stay up to date and informed.